Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
5 min read
Deep Scientific Insights on teprotumumab-trbw's R&D Progress, Mechanism of Action, and Drug Target
26 October 2023
This article summarized the latest R&D progress of teprotumumab-trbw, the Mechanism of Action for teprotumumab-trbw, and the drug target R&D trends for teprotumumab-trbw.
Latest Hotspot
3 min read
The KRAS G12C inhibitor IBI351 tablet by Innovent Biologics is set to be included in priority review for the treatment of advanced non-small cell lung cancer
26 October 2023
The Drug Evaluation Center of the NMPA in China announced on Oct 24, 2023, on its official site, that Innovent Biologics' Category 1 new drug, GFH925 (IBI351), is slated for priority review.
Drug Insights
4 min read
An In-depth Analysis of thioridazine hydrochloride's R&D Progress and Mechanism of Action on Drug Target
26 October 2023
This article summarized the latest R&D progress of thioridazine hydrochloride, the Mechanism of Action for thioridazine hydrochloride, and the drug target R&D trends for thioridazine hydrochloride.
Valuable Targets
4 min read
Advances in Clinical Research on NMDA Receptor Antagonist
26 October 2023
The N-Methyl-D-Aspartate (NMDA) receptor is a type of ionotropic glutamate receptor that plays a crucial role in excitatory synaptic transmission, plasticity, and excitotoxicity in the central nervous system, closely related to the body's memory, learning, and emotions.
Drug Insights
5 min read
Tolfenamic acid: Detailed Review of its Transformative R&D Success
26 October 2023
This article summarized the latest R&D progress of tolfenamic acid, the Mechanism of Action for tolfenamic acid, and the drug target R&D trends for tolfenamic acid.
Latest Hotspot
3 min read
Arvinas' two AR receptor PROTAC therapies show positive results in Phase 1/2 clinical trials
26 October 2023
Arvinas Inc. recently reported positive results for its AR-targeting protein degraders, bavdegalutamide (ARV-110) and ARV-766, in Phase 1/2 trials for mCRPC treatment at ESMO.
Drug Insights
4 min read
Taurolidine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
26 October 2023
This article summarized the latest R&D progress of taurolidine, the Mechanism of Action for taurolidine, and the drug target R&D trends for taurolidine.
Bio Sequence
3 min read
Mapping the Evolution of the Competitive Landscape of Mirvetuximab Soravtansine
26 October 2023
In mapping the evolutionary trajectory of the patenting landscape pertaining to Mirvetuximab Soravtansine, it is critical to analyze the strategic approach of the top 10 assignees. There is also a dynamic shift in the competition blueprint that is dictated by the progression of time.
Drug Insights
5 min read
Unleashing the Power of tamibarotene: A Comprehensive Review on R&D Breakthroughs
26 October 2023
This article summarized the latest R&D progress of tamibarotene, the Mechanism of Action for tamibarotene, and the drug target R&D trends for tamibarotene.
Latest Hotspot
3 min read
Immutep announces positive clinical results for two studies of its novel LAG-3 immunotherapy, eftilagimod alpha
25 October 2023
Immutep recently introduced its novel LAG-3 immunotherapy, Eftilagimod Alpha (Efti), for cancer and autoimmune disease treatment at the 2023 ESMO meeting. It presented positive data from two trials for Efti with pembrolizumab ± double chemotherapy as first-line NSCLC treatments.
Drug Insights
5 min read
A Comprehensive Review of sunvozertinib's R&D Innovations and Drug Target Mechanism
25 October 2023
This article summarized the latest R&D progress of sunvozertinib, the Mechanism of Action for sunvozertinib, and the drug target R&D trends for sunvozertinib.
Valuable Targets
6 min read
Analysis on the Research Progress of p53 inhibitors
25 October 2023
p53 inhibitors interfere with the normal function of the p53 protein and are primarily used as research tools to study the biological effects of p53 inactivation.